Related Experiment Video
Updated: Jan 5, 2026
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
Published on: March 5, 2019
Vaccine Targeted Alpha 1D-Adrenergic Receptor for Hypertension
Chang Li1,2,3, Xiaole Yan1,2,3, Danyu Wu1,2,3
1From the Department of Cardiology (C.L., X.Y., D.W., K.Z., Y.P., Y.Z., F.C., X.C., S.Y., Z.Z., Y.W., Y.L., Z.Q.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Insights
A novel vaccine targeting the α1D-adrenergic receptor (α1D-AR) effectively lowered blood pressure in hypertensive rat models. This vaccine demonstrated target organ protection and reduced α1D-AR expression without significant immune damage, offering a promising hypertension treatment.
Area of Science:
- Cardiovascular Pharmacology
- Immunotherapy
- Hypertension Research
Background:
- Current α1-adrenergic receptor (α1-AR) blockers lack subtype selectivity, have short half-lives, and their role in cardiovascular events is unclear.
- There is a clinical need for more selective and effective antihypertensive therapies.
- Targeting the α1D-AR subtype presents a potential avenue for novel hypertension treatment.
Purpose of the Study:
- To develop and evaluate a vaccine specifically targeting the α1D-adrenergic receptor (α1D-AR) for hypertension treatment.
- To assess the antihypertensive efficacy and target organ protective effects of the ADRQβ-004 vaccine.
- To investigate potential immune-mediated damage associated with the vaccine.
Main Methods:
- Screening of a short peptide (ADR-004) specific to α1D-AR.
- Production of the ADRQβ-004 vaccine and administration to spontaneously hypertensive rats (SHR) and NG-nitro-l-arginine methyl ester + SHR models.
- Evaluation of blood pressure reduction, target organ protection (vascular, cardiac, renal), α1D-AR and α1A-AR expression, and immune-mediated damage.
Main Results:
- The ADRQβ-004 vaccine demonstrated strong immunogenicity, inducing significant antibody production.
- Systolic blood pressure decreased by an average of 15 mm Hg in SHR and 29 mm Hg in the combined model in short-term studies.
- Long-term studies showed a stable antihypertensive effect (average decline of 22 mm Hg), preventing vascular remodeling, cardiac hypertrophy/fibrosis, and renal injury, outperforming prazosin at the renal level.
- The vaccine downregulated α1D-AR expression without affecting α1A-AR and caused no significant immune-mediated damage.
Conclusions:
- The ADRQβ-004 vaccine is a potent antihypertensive agent targeting α1D-AR.
- It offers significant protection against target organ damage in hypertensive models.
- The vaccine represents a novel and promising therapeutic strategy for hypertension management.
Abstract:
The α1-AR (α1 adrenergic receptor) blockers currently on the market cannot meet clinical needs because of low-selectivity for subtypes of α1-ARs, short half-life, and uncertain role in cardiovascular end point events. The study sought to find a vaccine specifically against α1D-AR (α1D-adrenergic receptor) for treating hypertension. A short peptide ADR-004 (cgiteeagy) belonging to α1D-AR was screened, and the ADRQβ-004 vaccine was produced and injected into spontaneously hypertensive rats model (including a short-term study, 10 weeks, and a long-term observation study, 39 weeks) and NG-nitro-l-arginine methyl ester + spontaneously hypertensive rats model (15 weeks). The antihypertensive effect and target organ protection of the ADRQβ-004 vaccine were carefully evaluated. The possible immune-mediated damage was detected in normal vaccinated Sprague Dawley rats. The ADR-004 peptide has perfect immunogenicity, and the ADRQβ-004 vaccine could induce strong antibody production. In the short-term study, the ADRQβ-004 vaccine averagely decreased the systolic blood pressure of spontaneously hypertensive rats up to 15 mm Hg and that of NG-nitro-l-arginine methyl ester+spontaneously hypertensive rats up to 29 mm Hg. In the long-term observation model, the antihypertensive effect of the ADRQβ-004 vaccine was quite stable, and the average decline of systolic blood pressure was 22 mm Hg. The ADRQβ-004 vaccine effectively prevented vascular structural remodeling, cardiac hypertrophy and fibrosis, and renal injury of hypertensive animals, superior to prazosin at renal level. Moreover, the ADRQβ-004 vaccine obviously downregulated the expression of α1D-AR, but not α1A-AR. Additionally, no significant immune-mediated damage was detected in immunized animals. The present results demonstrate that the ADRQβ-004 vaccine may provide a novel and promising method for the treatment of hypertension.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:17Antihypertensive Drugs: Action of β1 Blockers
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:25Antihypertensive Drugs: Direct Renin Inhibitors